摘要 |
<p>The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.</p> |
申请人 |
EXELIXIS, INC.;BOLLU, VENKATAIAH;BOREN, BRANT, CLAYTON;DALGARD, JACKLINE, EVE;FLATT, BRENTON, T.;HAQ, NADIA;HUDSON, SARAH;MOHAN, RAJU;MORRISSEY, MICHAEL;PRATT, BENJAMIN;WANG, TIE-LIN |
发明人 |
BOLLU, VENKATAIAH;BOREN, BRANT, CLAYTON;DALGARD, JACKLINE, EVE;FLATT, BRENTON, T.;HAQ, NADIA;HUDSON, SARAH;MOHAN, RAJU;MORRISSEY, MICHAEL;PRATT, BENJAMIN;WANG, TIE-LIN |